Our platform unlocks cryptic biosynthetic potential while obviating the need for cloning, genetic manipulation, and complex procedures.
Although historically prolific, recent investments into natural products have delivered diminishing returns due to the costly rediscovery of known compounds. This is in part due to the transcriptionally silent nature of most biosynthetic genes: conventional approaches only capture ~10% of a bacterium’s biosynthetic potential.
Using a broadly applicable, high-throughput, genetics-free, cloning-free approach, the Cryptyx Biosciences HiTES (High-Throughput Elicitor Screening) platform accesses >90% of this cryptic biosynthetic potential in a rapid and parallel manner.
HiTES Platform
Reporter-Guided
Delivers natural products from specific biosynthetic pathways.
Imaging Mass Spectrometry-Guided
Reveals global secondary metabolism for a selected strain and prioritizes novel chemical matter.
Bioactivity-Guided
Yields desired bioactive metabolites.
Stimulating Cryptic Natural Products
The HiTES platform is highly versatile and can be applied to any microorganism to enhance production of known natural products or induce entirely new products. The Cryptyx Bioscience HiTES platform is offered to developers of natural drug and therapeutic products as a genetics-free, cloning-free, rapid, and reliable solution to the traditional complexities of production.
In the figure above, we show differential transcriptomic and proteomic data of 22 gene clusters in response to an elicitor identified by the HiTES platform. 21 out of 22 gene clusters are induced in response to that elicitor.